Strongbridge Biopharma plc (SBBP) Hit 52-Week Low

July 16, 2018 - By Lisa Delgado

Strongbridge Biopharma plc (NASDAQ:SBBP) Logo

The stock of Strongbridge Biopharma plc (NASDAQ:SBBP) hit a new 52-week low and has $4.65 target or 7.00 % below today’s $5.00 share price. The 7 months bearish chart indicates high risk for the $227.67 million company. The 1-year low was reported on Jul, 16 by Barchart.com. If the $4.65 price target is reached, the company will be worth $15.94M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 9.09% or $0.5 during the last trading session, reaching $5. About 520,203 shares traded or 43.14% up from the average. Strongbridge Biopharma plc (NASDAQ:SBBP) has risen 60.64% since July 16, 2017 and is uptrending. It has outperformed by 48.07% the S&P500.

Analysts await Strongbridge Biopharma plc (NASDAQ:SBBP) to report earnings on August, 6. They expect $-0.44 earnings per share, down 29.41 % or $0.10 from last year’s $-0.34 per share. After $-0.66 actual earnings per share reported by Strongbridge Biopharma plc for the previous quarter, Wall Street now forecasts -33.33 % EPS growth.

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States, Sweden, and Cayman Islands. The company has market cap of $227.67 million. The firm offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. It currently has negative earnings. It is also involved in developing Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical development for the treatment of endogenous CushingÂ’s syndrome; and Veldoreotide, a novel somatostatin analogue that is in Phase II clinical development to treat acromegaly.

Strongbridge Biopharma plc (NASDAQ:SBBP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.